GAP-f resources

GAP-f resources

Peer-reviewed publications

Rome Action Plan  

The Rome Action Plan is a compilation of commitments by key stakeholders to accelerate research, development, registration, introduction and uptake of HIV & TB diagnostics and medicines for children, with the ultimate objective of reducing morbidity and mortality. 

Resolution

Media

Posters

The Global Accelerator for Paediatric Formulations (GAP-f)

Accelerating the development and uptake of the most needed drug formulations for children 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology – Morin, Cohn, Vicari, Domanico, Lewis, Watkins, Pascual, Lee, Sugandhi, Eisenhawer, Pérez Casas, Auton, Siberry, Giaquinto, Penazzato, On behalf of GAP-f partners — March 2018 | Granada, Spain

Online resources

Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations
Cressey, Abbassi, Lallemant, Indolfi, Al-Nahari, Farid, Penazzato, Easterbrook & El-Sayed – PIDJ, 2021, 40(12): 1081-1086

Enpr-EMA – European Network of Paediatric Research at the European Medicines Agency  
Network of research networks, investigators and centres with recognised expertise in performing clinical studies in childrens

GPFC – Goodman Pediatric Formulations Centre (GPFC) 
Rosalind & Morris Goodman Family Pediatric Formulations Centre of the CHU Sainte-Justine 

LEAP – Long-Acting / Extended Release Antiretroviral Resource Program  
Portal funded by the U.S. National Institutes of Health 

MAP-IT Model – Model for Assessment of Pediatric Interventions for Tuberculosis  
RTI International, TB Alliance, Unitaid 

Paed Form – European Paediatric Formulary  
Council of Europe 

Pediatric COVID-19 therapeutics: Seizing the right research and development opportunities to accelerate access for children
Morin, Lallemant, Garcia-Prats, Lewis, Watkins, Giaquinto, Valentin, Penazzato & Reeder – PIDJ, 2022, 41(1): e1-e5

STEP database – Safety & Toxicity of Excipients for Paediatrics 
European Paediatric Formulation Initiative 

USPFI – United States Pediatric Formulation Initiative  
In the context of the Best Pharmaceuticals for Children Act (BPCA) and with groups focused on scientific/technical/regulatory barriers, taste/smell/flavour, economics/partnerships, and use/application of new delivery systems 

Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations
Cressey, Abbassi, Lallemant, Indolfi, Al-Nahari, Farid, Penazzato, Easterbrook & El-Sayed – PIDJ, 2021, 40(12): 1081-1086